A coronavirus vaccine developed by China's Sinovac showed "general efficacy" of 50.4% in a late-stage trial in Brazil, researchers said on Tuesday, barely enough for regulatory approval and far short of earlier indications....
The Real Time News
More Stories
Trump asks court to let him dodge rape accuser’s suit
As WHO begins Covid origin probe, US releases fact sheet on Wuhan lab that ‘deserve scrutiny’
Indonesian teams find more bodies after earthquake, death toll rises to 56